This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advertisements

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Clinical Trials in IBD.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Advances in Managing Inhibitors in Patients With Hemophilia A

5 Things NPs and PAs Need to Know About Tardive Dyskinesia

Exploring the Spectrum of Excessive Daytime Sleepiness

Progression After Cancer Immunotherapy in Advanced NSCLC

Ask the Onychomycosis Expert, Part 2

Ask the Onychomycosis Expert, Part 1

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

New Standards of Care in ALK-Translocated Advanced NSCLC

Improving Acne Outcomes

Extended Half-life Factor Products in the Management of Hemophilia

Case Challenges in Chronic Migraine

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Issues in the Management of Hemophilia: A Best Practice Series

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Oral Anticoagulants in AFa,b A Brief History.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Chronic Idiopathic Urticaria

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Tailoring Hemophilia Prophylaxis Therapy

The Nurse View.

Addressing Disease Burden in Asthma

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Improving Outcomes in OSA

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Individualizing Factor Replacement Therapy for Patients With Hemophilia.

Evaluating Next-Generation BTK Inhibitors

EHL Technologies in Hemophilia Care

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Immunotherapy for cSCC

When Is Biologic Therapy Appropriate for HS?

Program Goals. Technological Advances in Longer-Acting Factor Replacement Therapy for Hemophilia.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Parkinson Disease Psychosis

What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?

Immune Checkpoint Inhibitors in Lung Cancer

Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B.

IgG-Fc Fusion Proteins and Immunomodulation: What Does the Science Tell Us?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Extended Half-life Factor Products in the Management of Hemophilia

Updates From the 2015 Meetings in Hemophilia

Evaluating BTK Inhibitors in CLL

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Optimizing Joint Health in Hemophilia

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Selecting Treatment Approaches in Hemophilia

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

CDK4/6 Inhibitors.

Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Dr. Festus Njuguna Moi University/MTRH

Immune Checkpoint Inhibitors in Lung Cancer

Perspectives on Revised European Guidelines on Management of Bleeding and Coagulopathy Following Major Trauma.

Examining the Role of Pharmacokinetics in Hemophilia

Presentation transcript:

EHL Factor Products in Hemophilia: An Update for Pharmacists and Lab Technicians

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

EHL Factor Products in Hemophilia

Hemophilia

Hemophilia (cont)

Categorization of the Severity of Hemophilia

Recombinant Factor Generations

rFVIII Products First and Second Generation

rFVIII Products Third Generation

rFIX Products

Half-Life of Standard Factor Products

Fc Fusion Clotting Proteins

Fc Fusion Clotting Proteins (cont)

PEGylated and GlycoPEGylated Clotting Proteins

PEGylated and GlycoPEGylated Clotting Proteins (cont)

Albumin Fusion Clotting Proteins

FVIII Dosing

FIX Dosing

Inhibitors

Conclusions

Monitoring EHL Factor Products

Monitoring

Laboratory Monitoring Overview

OSA

CSA

Differences Between OSA and CSA

Patient Case

Discrepancies Between OSA and CSA

Discrepancies Between OSA and CSA (cont)

Discrepancies Between OSA and CSA for Modified FVIII Products

Discrepancies Between OSA and CSA for Modified FIX Products

Discrepancies Between OSA and CSA for Modified Factor Products

Strategies in Overcoming Assay Discrepancies

Pharmacist Role in Laboratory Monitoring

Clinical Monitoring of Modified Factor Products

Treatment Log

Management of Bleeding Episodes

Pharmacist Role in Clinical Monitoring

Abbreviations